Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.49 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23140704 | 1.00 | KLK5 (0.49) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL23140735 | 0.90 | ACE (0.51) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL15083163 | 0.90 | ACE (0.51) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL6263802 | 0.89 | PPARA (0.58) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL8316215 | 0.89 | PPARA (0.58) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL12873045 | 0.89 | PPARA (0.58) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL23056382 | 0.88 | ACE (0.49) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL25491606 | 0.85 | KLK7 (0.59) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL5419241 | 0.85 | KLK7 (0.59) | KLK5KLK7TACR1PPARASYK | |
| SCHEMBL25715928 | 0.84 | PPARA (0.56) | KLK5KLK7TACR1PPARASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | KLK5 403/4885KLK7 326/4885TACR1 172/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KLK5 403/4885KLK7 326/4885TACR1 172/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KLK5 403/4885KLK7 326/4885TACR1 172/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KLK5 403/4885KLK7 326/4885TACR1 172/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | KLK5 403/4885KLK7 326/4885TACR1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.